Chemomab Therapeutics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMMB research report →
Companywww.chemomab.com
Chemomab Therapeutics Ltd. , a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- CEO
- Adi Mor George
- IPO
- 2019
- Employees
- 20
- HQ
- Tel Aviv, IL
Price Chart
Valuation
- Market Cap
- $10.22M
- P/E
- -1.78
- P/S
- 0.00
- P/B
- 1.24
- EV/EBITDA
- -0.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -67.81%
- ROIC
- -74.21%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,995,000 · 35.50%
- EPS
- $-1.42 · 54.51%
- Op Income
- $-9,567,000
- FCF YoY
- 27.41%
Performance & Tape
- 52W High
- $5.77
- 52W Low
- $1.35
- 50D MA
- $1.69
- 200D MA
- $2.31
- Beta
- 0.51
- Avg Volume
- 52.49K
Get TickerSpark's AI analysis on CMMB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Mor George Adi | other | 0 |
| Mar 18, 26 | Mor George Adi | other | 0 |
| Mar 18, 26 | Mor George Adi | other | 0 |
| Mar 18, 26 | Mor George Adi | other | 0 |
| Mar 18, 26 | Mor George Adi | other | 32,925 |
| Mar 18, 26 | Mor George Adi | other | 109,718 |
| Mar 18, 26 | Mor George Adi | other | 8,431 |
| Mar 18, 26 | Darvish Nissim | other | 0 |
| Mar 18, 26 | Darvish Nissim | other | 2,531 |
| Mar 18, 26 | Darvish Nissim | other | 2,971 |
Our CMMB Coverage
We haven't published any research on CMMB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMMB Report →